medicasolution

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc.

Results of a large national study show that nearly three-quarters of obese patients with type 2 diabetes who undergo weight-loss surgery are able to stop insulin and other antidiabetes drugs within si

JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the es

Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.

The trailblazing company whose Smart for Life weight management products featuring the cookie diet component has recently improved its Chocolate Chip Cookie to include the most protein offered in a me

Melbourne researchers from the Walter and Eliza Hall Institute have found that inflammatory cells in fat tissue cause the body to become resistant to the effects of insulin – a common precursor to typ

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progressi

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20).

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells.

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage cli